BI 1356225
Alternative Names: BI-1356225Latest Information Update: 28 Oct 2022
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Obesity in Germany (PO, Tablet)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Obesity(In volunteers) in Germany (PO, Liquid)
- 30 Jun 2020 Boehringer Ingelheim plans a pharmacokinetic phase I trial (In volunteers) In June 2020 (PO) (NCT04447261) (EudraCT2020-000342-34)